1. Able to sign and date the Informed Consent Form (ICF)
2. ≥18 years of age, at the time of signing informed consent
3. Diagnosis of B-cell non-Hodgkin lymphoma (B-NHL), including the following neoplasms as defined by the 2022 WHO classification of lymphoid neoplasms:
1. Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS)
2. Primary mediastinal large B-cell lymphoma (PMBCL)
3. Transformed follicular lymphoma (tFL) (Pathology report is required to clarify DLBCL rather than follicular lymphoma (FL) with local/minor progression to DLBCL)
4. Diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements (DLBCL/HGBL-MYC/BCL2)
5. High-grade B-cell lymphoma (HGBL), NOS
6. Follicular large B-cell lymphoma (FLBL) (At least 2 pathological diagnoses of follicular lymphoma grade 3B \[FL3b\] at different times are required, and the most recent pathology used for screening is FL3b or FLBL)
4. R/R disease after ≥2 lines of standard therapy, including FDA approved, commercially available CAR T-cell therapy for at least 3 months since previous CAR T-cell therapy treatment.
5. Measurable disease per the Lugano 2014 Classification
3. Prior treatment with any investigational CAR T-cell therapy
Clareo Health | Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
